Skip to main content
Dosing started for beta thalassemia candidate in midstage trial
1/10/2019

Protagonist Therapeutics' midstage clinical trial has initiated dosing for its first patient to assess its injectable hepcidin mimetic peptide candidate PTG-300 as a treatment for patients with beta thalassemia. The study will evaluate PTG-300 in transfusion-dependent and non-transfusion-dependent patients, with preliminary data possibly available in the second half of 2019.

Full Story: